Panitumumab

CAS No. 339177-26-3

Panitumumab( —— )

Catalog No. M22158 CAS No. 339177-26-3

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 484 In Stock
10MG 691 In Stock
25MG 1035 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Panitumumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
  • Description
    Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
  • In Vitro
    Western Blot Analysis Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells Concentration:2, 20, 200, 2000 nM Incubation Time:3 h Result:Inhibited ligand-induced autophosphorylation of EGFR.
  • In Vivo
    Animal Model:NCI-H1975 and NCI-H1650 xenografts Dosage:25, 100, or 500 μg/mouse Administration:Intraperitoneal injection (i.p.), twice a week Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    339177-26-3
  • Formula Weight
    147 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cohenuram M, et al.Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007 Jan;18(1):7-15.
molnova catalog
related products
  • Cimigenoside

    Cimigenoside is an active compound from genus Cimicifuga.

  • WHI-P154

    WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.

  • Theliatinib

    Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.